$ESPR
Esperion Therapeutics, Inc. Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023016646 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$25.79M	$24.33M	$18.84M
YoY Change	36.86%	29.16%	136.1%
Cost Of Revenue	$6.786M	$11.65M	$7.125M
YoY Change	-26.05%	63.54%	295.83%
Gross Profit	$19.00M	$12.68M	$11.71M
YoY Change	96.59%	8.25%	88.89%
Gross Profit Margin	73.68%	52.11%	62.17%
Selling, General & Admin	$33.96M	$29.90M	$30.38M
YoY Change	14.69%	-1.58%	-50.25%
% of Gross Profit	178.73%	235.87%	259.42%
Research & Development	$22.10M	$31.38M	$24.32M
YoY Change	-31.86%	29.04%	-13.0%
% of Gross Profit	116.31%	247.54%	207.66%
Depreciation & Amortization	$51.00K	$81.00K	$153.0K
YoY Change	-66.0%	-47.06%	0.0%
% of Gross Profit	0.27%	0.64%	1.31%
Operating Expenses	$56.06M	$72.93M	$61.83M
YoY Change	-21.29%	17.97%	-31.91%
Operating Profit	-$37.06M	-$48.61M	-$42.99M
YoY Change	-29.25%	13.06%	-48.1%
Interest Expense	-$14.44M	$14.39M	$14.06M
YoY Change	-201.2%	2.31%	73.07%
% of Operating Profit
Other Income/Expense, Net	$1.560M	$1.273M	$320.0K
YoY Change	390.57%	297.81%	2185.71%
Pretax Income	-$49.94M	-$61.72M	-$56.73M
YoY Change	-24.71%	8.79%	-37.59%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$49.94M	-$61.72M	-$56.73M
YoY Change	-24.71%	8.79%	-37.61%
Net Earnings / Revenue	-193.65%	-253.68%	-301.18%
Basic Earnings Per Share	-$0.46	-$0.79	-$0.93
Diluted Earnings Per Share	-$0.46	-$0.79	-$0.93
COMMON SHARES
Basic Shares Outstanding	94.71M shares	76.57M shares	60.95M shares
Diluted Shares Outstanding	109.2M shares	78.44M shares	60.95M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$138.5M	$162.3M	$218.5M
YoY Change	-25.49%	-25.7%	0.28%
Cash & Equivalents	$138.5M	$144.9M	$150.4M
Short-Term Investments	$0.00	$17.43M	$68.14M
Other Short-Term Assets	$7.180M	$12.50M	$11.55M
YoY Change	-24.87%	8.25%	-6.88%
Inventory	$45.68M	$39.35M	$35.65M
Prepaid Expenses
Receivables	$40.80M	$36.42M	$25.12M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$232.1M	$250.6M	$290.8M
YoY Change	-8.06%	-13.83%	6.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.445M	$83.00K	$511.0K
YoY Change	577.29%	-83.76%	-54.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$50.00M
YoY Change
Total Long-Term Assets	$2.501M	$1.214M	$52.03M
YoY Change	-95.14%	-97.67%	762.78%
TOTAL ASSETS
Total Short-Term Assets	$232.1M	$250.6M	$290.8M
Total Long-Term Assets	$2.501M	$1.214M	$52.03M
Total Assets	$234.6M	$251.8M	$342.9M
YoY Change	-22.82%	-26.55%	23.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.56M	$17.07M	$26.83M
YoY Change	91.38%	-36.39%	-11.58%
Accrued Expenses	$44.20M	$39.34M	$35.07M
YoY Change	4.13%	12.19%	-40.26%
Deferred Revenue	$15.63M	$12.16M	$3.795M
YoY Change	210.94%	220.34%	49.23%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$107.2M	$95.49M	$79.09M
YoY Change	30.26%	20.74%	-19.21%
LONG-TERM LIABILITIES
Long-Term Debt	$260.7M	$260.3M	$258.7M
YoY Change	0.64%	0.63%	-4.79%
Other Long-Term Liabilities	$238.7M	$225.7M	$254.1M
YoY Change	-6.15%	-11.2%	19600.0%
Total Long-Term Liabilities	$499.4M	$486.0M	$512.8M
YoY Change	-2.72%	-5.23%	39652.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$107.2M	$95.49M	$79.09M
Total Long-Term Liabilities	$499.4M	$486.0M	$512.8M
Total Liabilities	$606.6M	$581.5M	$591.9M
YoY Change	1.83%	-1.76%	8.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.452B	-$1.402B	-$1.163B
YoY Change	18.08%	20.52%	25.31%
Common Stock	$101.0K	$87.00K	$61.00K
YoY Change	55.38%	42.62%	134.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$55.00M	$55.00M	$55.00M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares		1.994M shares	1.994M shares
Shareholders Equity	-$372.0M	-$329.7M	-$249.0M
YoY Change
Total Liabilities & Shareholders Equity	$234.6M	$251.8M	$342.9M
YoY Change	-22.82%	-26.55%	23.06%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$49.94M	-$61.72M	-$56.73M
YoY Change	-24.71%	8.79%	-37.61%
Depreciation, Depletion And Amortization	$51.00K	$81.00K	$153.0K
YoY Change	-66.0%	-47.06%	0.0%
Cash From Operating Activities	-$24.75M	-$54.36M	-$38.99M
YoY Change	-51.02%	39.41%	-56.22%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$17.50M	$25.00M	-$18.10M
YoY Change	250.0%	-238.11%
Cash From Investing Activities	$17.50M	$25.00M	-$18.10M
YoY Change	250.0%	-238.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	809.0K	$49.49M	-$1.436M
YoY Change	-95.53%	-3546.52%	-170.22%
NET CHANGE
Cash From Operating Activities	-24.75M	-$54.36M	-$38.99M
Cash From Investing Activities	17.50M	$25.00M	-$18.10M
Cash From Financing Activities	809.0K	$49.49M	-$1.436M
Net Change In Cash	-6.441M	$20.14M	-$58.53M
YoY Change	-76.51%	-134.4%	-32.74%
FREE CASH FLOW
Cash From Operating Activities	-$24.75M	-$54.36M	-$38.99M
Capital Expenditures		$0.00
Free Cash Flow		-$54.36M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-35986
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1870780
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3891 Ranchero Drive, Suite 150
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48108
CY2023Q1	dei	City Area Code CityAreaCode	734
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	887-3903
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ESPR
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	94712657	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144911000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	124775000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	17427000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	42086000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36415000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33729000	usd
CY2023Q1	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	6916000	usd
CY2022Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	1026000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	39352000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	35201000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5584000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9866000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	250605000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	246683000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1075000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1036000	usd
CY2023Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	usd
CY2023Q1	us-gaap	Assets Assets	251819000	usd
CY2022Q4	us-gaap	Assets Assets	247939000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	17065000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	23040000	usd
CY2023Q1	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	4617000	usd
CY2022Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	5426000	usd
CY2023Q1	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	34421000	usd
CY2022Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	35191000	usd
CY2023Q1	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	26921000	usd
CY2022Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	24760000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12157000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3507000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	305000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	384000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	95486000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92308000	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	260316000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	259899000	usd
CY2023Q1	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	224898000	usd
CY2022Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	218845000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	782000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	665000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	581482000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	571717000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89237167	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	76564396	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	87000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	75000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1127004000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1071183000	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2023Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1401755000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1340036000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-329663000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-323778000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	251819000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	247939000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24329000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18836000	usd
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	11652000	usd
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	7125000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	31381000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	24319000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29901000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30381000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	72934000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	61825000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-48605000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-42989000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	14387000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	14062000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1273000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	320000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-61719000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-56731000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78440266	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78440266	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60954755	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60954755	shares
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-232000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61718000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56963000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-196944000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	431000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4436000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-232000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-56731000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-249040000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-323778000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	502000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2903000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	52428000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-61719000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-329663000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-61719000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-56731000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	81000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	153000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	339000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-173000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	417000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	398000	usd
CY2023Q1	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	11320000	usd
CY2022Q1	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	11015000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2903000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4436000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2686000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2182000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1608000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-764000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8650000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2100000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4151000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1260000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5975000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9393000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1249000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3049000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54356000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38990000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	18102000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	25000000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25000000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18102000	usd
CY2023Q1	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	3106000	usd
CY2022Q1	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	1217000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	52598000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	52598000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	219000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49492000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1436000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20136000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-58528000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124775000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	258892000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	144911000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200364000	usd
CY2023Q1	espr	Common Stock Issuance Costs Incurred Not Yet Paid CommonStockIssuanceCostsIncurredNotYetPaid	170000	usd
CY2022Q1	espr	Common Stock Issuance Costs Incurred Not Yet Paid CommonStockIssuanceCostsIncurredNotYetPaid	0	usd
CY2023Q1	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	1000	usd
CY2022Q1	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	6000	usd
CY2019Q3	espr	Number Of Study Patients NumberOfStudyPatients	14000	patient
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March 31, 2023, eleven customers accounted for all of the </span></div>Company's net trade receivables and as of December 31, 2022, eleven customers accounted for all the Company's net trade receivables.
CY2023Q1	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	35090000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	26558000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1697000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	6548000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2565000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2095000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	39352000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	35201000	usd
CY2023Q1	espr	Potential Proceeds From Partner Milestone Payments PotentialProceedsFromPartnerMilestonePayments	300000000	usd
CY2023Q1	espr	Potential Proceeds From Partner Milestone Payments PotentialProceedsFromPartnerMilestonePayments	300000000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	131395000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	131394000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	152562000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	152560000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	usd
CY2023Q1	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
CY2022Q1	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
CY2022	espr	One Time Partial Call OneTimePartialCall	50000000	usd
CY2023Q1	espr	Revenue Interest Payments Redemption Percentage RevenueInterestPaymentsRedemptionPercentage	2.25
CY2023Q1	espr	Revenue Interest Payments Redemption Value RevenueInterestPaymentsRedemptionValue	400000000	usd
CY2023Q1	espr	Revenue Interest Payments Remaining Redemption Value RevenueInterestPaymentsRemainingRedemptionValue	385000000	usd
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	usd
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	usd
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	usd
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	usd
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1994198	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	165540	shares
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5565000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9053000	usd
CY2023Q1	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	21313000	usd
CY2022Q4	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	21987000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3446000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2547000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	3975000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1325000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	122000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	279000	usd
CY2023Q1	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	34421000	usd
CY2022Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	35191000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3842737	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.75
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M9D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1658000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1154300	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.23
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	622585	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	38.72
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4374452	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.98
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M4D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4374452	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.98
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M4D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2194004	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.44
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y11M26D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	50000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2900000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	91100780	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36964286	shares
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	50000000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	86292792	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51816979	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144911000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150364000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	124775000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208892000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	144911000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200364000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124775000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	258892000	usd

Files In Submission

Name	View Source	Status
espr-20230331_lab.xml	Edgar Link	unprocessable
0001628280-23-016646-index-headers.html	Edgar Link	pending
0001628280-23-016646-index.html	Edgar Link	pending
0001628280-23-016646.txt	Edgar Link	pending
0001628280-23-016646-xbrl.zip	Edgar Link	pending
espr-20230331.htm	Edgar Link	pending
espr-20230331.xsd	Edgar Link	pending
espr-20230331_cal.xml	Edgar Link	unprocessable
espr-20230331_def.xml	Edgar Link	unprocessable
espr-20230331_htm.xml	Edgar Link	completed
espr-ex311x03312023.htm	Edgar Link	pending
espr-ex312x03312023.htm	Edgar Link	pending
espr-ex321x03312023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
espr-20230331_pre.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics, Inc. Stock $espr

2023 Q2 Form 10-Q Financial Statement

#000162828023016646 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics, Inc. Stock $espr

2023 Q2 Form 10-Q Financial Statement

#000162828023016646 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics, Inc. Stock $espr